- Title
-
Bio Law Blog
-
Welcome to the Bio Law Blog. Our blog shares insights into intellectual property law for biologic medicines and related regulatory and legislative developments. We started this blog to engage in a conversation about the rapidly developing U.S. biosimilars pathway (the Biologics Price Competition and Innovation Act) and the recent surge in approvals for cutting-edge biologic products, such as siRNAs and cell-based and gene therapies. These new biologic products are changing medicine and posing new intellectual property questions and challenges. We also analyze developments in written description and enablement law for antibodies, the impact of Section 101 on biotech discoveries, and the increasing role of the Patent Trial and Appeal Board in reviewing biotech patents. We share a perspective as trial lawyers immersed in biology and biotech patent law.
We are excited to be part of these transformative times for biologic medicines and to discuss them with you. We hope you enjoy our blog, and we welcome any questions, comments or suggestions.
Featured Posts
Recent Posts
Featured Perspectives
Editors
-
-
Jonathan S. Caplan
-
- Partner
- Partner, Co-Chair, Intellectual Property
- New York
- vcard
-
-
-
People
-
-
Jonathan S. Caplan
-
- Partner
- Partner, Co-Chair, Intellectual Property
- New York
- vcard
-
-
-
Marcus A. Colucci
-
- Special Counsel
- New York
- vcard
-
-
-
Jenna Fuller
-
- Associate
- New York
- vcard
-
-
-
Timothy Layden
-
- Associate
- Silicon Valley
- vcard
-
-
-
André Pineda, Ph.D.
-
- Scientific Advisor
- New York
- vcard
-
-
-
Jeffrey H. Price
-
- Special Counsel
- New York
- vcard
-
-
-
Perspectives
